TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06624670: A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum

Sponsor: LEO Pharma · Phase: PHASE3 · Area: DERMATOLOGY_AESTHETIC · Target Enrollment: 90 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$2,820,972

Rescue Site Savings

+$1,868,436

Unlock Full NCT06624670 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06624670 Rescue Dossier →